C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License
C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop and market an oral therapy for the treatment of inflammatory and respiratory diseases, with a primary focus on chronic obstructive pulmonary disease (COPD).
COPD is the third leading cause of death in the world, accounting for 3.23 million deaths in 2019. However, it is a preventable and treatable chronic lung disease that affects both men and women worl...
